Business Overview
Revvity, Inc. (NYSE: RVTY) operates through two primary business segments, Life Sciences and Diagnostics. The company provides instruments, consumables, and software solutions supporting laboratory workflows across research, biopharmaceutical development, and clinical diagnostics markets. Operations are conducted globally with a focus on recurring consumables and workflow-based offerings.
Financial Performance
For the fourth quarter ended December 2025, Revvity reported consolidated revenue of $772.1 million, compared with $729.4 million in the same quarter of the prior year. GAAP net income for the quarter was $98.4 million, versus $94.6 million a year earlier. Diluted earnings per share were $0.87, while adjusted earnings per share from continuing operations were $1.70. Adjusted operating income from continuing operations totaled $229.4 million, resulting in an adjusted operating margin of 29.7%. For the full fiscal year, revenue totaled $2.86 billion, compared with $2.83 billion in the prior year. GAAP net income for the year was $346.9 million, versus $349.3 million previously.
Operating Metrics
Segment performance for the reported quarter showed Life Sciences revenue of $382.0 million with adjusted operating income of $136.0 million, while Diagnostics revenue was $390.1 million with adjusted operating income of $91.4 million. Quarterly revenue trends reflect reported growth year over year.
Key Developments
During the quarter, the company reiterated its focus on diagnostics workflow investments and selective product introductions aligned with existing platforms. Management referenced continued execution on previously announced portfolio actions and internal efficiency initiatives.
Risks and Constraints
Key risks outlined in company disclosures include execution risk related to integration of prior portfolio actions, supply chain variability, regulatory review timelines affecting product launches, and potential margin pressure from input costs. Currency movements and macroeconomic conditions may also affect reported results.
Outlook / Guidance
The company issued full-year 2026 guidance, indicating expected revenue in the range of $2.96 billion to $2.99 billion and adjusted earnings per share between $5.35 and $5.45. Investors will monitor quarterly progress toward these ranges and segment-level organic growth trends.
Performance summary
Shares closed at $108.80, up 0.29% on the day. Fourth-quarter revenue was $772.1 million with adjusted earnings per share of $1.70. Diagnostics contributed higher organic growth relative to Life Sciences during the reported period.
